Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

nded periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single minipump placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity. For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  St. Vincent Healthcare is ... care. Already following strict disinfection routines, St. Vincent ... to eliminate harmful germs, like Ebola, methicillin-resistant ... that can infect patients during their hospital stay. ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
(Date:4/21/2015)... , April 21, 2015   iRhythm Technologies, ... the advancement of cardiac care, announced today that Banner ... in the U.S., will now be offering iRhythm,s ZIO ... continuous cardiac monitoring. "At Banner Health, we ... patient outcomes and services," said John Hensing , ...
(Date:4/21/2015)... 21, 2015 Workers, compensation pharmacy spending increased ... in utilization helped offset a 7 percent increase in ... today by Express Scripts (NASDAQ: ESRX ). ... Trend Report discusses the overall pharmacy trend as well ... Opioid Management Mitigates Spend Increases ...
Breaking Medicine Technology:St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 2Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4
... 10, 2011 ThermoGenesis Corp. (Nasdaq: KOOL ... that process and store adult stem cells, said today ... Biotechnology Co., Ltd ("Beike"), a leading stem cell and ... agreement, ThermoGenesis will supply Beike with an initial stocking ...
... The Consumer Healthcare Products Association (CHPA) is pleased to ... Act, introduced today by Senator Kay Bailey Hutchison (R-Tex.) ... repeal a requirement enacted into law as part of ... that requires consumers to obtain a prescription in order ...
Cached Medicine Technology:ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 2ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 3ThermoGenesis Announces Agreement for AXP and BioArchive Cord Blood Systems With Major Chinese Stem Cell Company 4CHPA Applauds Introduction of The Patients' Freedom to Choose Act 2
(Date:4/21/2015)... Carinsurancehints.com has released a new blog post presenting ... auto insurance prices . , Commuting on ... should review their insurance options before deciding what plan ... forms. Some of the popular policies provide liability, collision ... rates and find the best prices in their area ...
(Date:4/21/2015)... 21, 2015 Edward Avalos, USDA Under ... Kawamura, former Secretary of the California Department of Food ... the 2nd Annual GrowRIVERSIDE Conference: The Future of Local ... inclusion of these nationally known experts intensifies an already ... farmers and others slated to speak at the June ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 Respected ... PACS® strategy , Visage Imaging Inc. (“Visage”), ... PME), has signed a seven-year contract with University ... in Northern Florida. The deal furthers the penetration ... hospital space, a key area of the North American ...
(Date:4/21/2015)... 2015 Wojo Nutrition announces ... innovation at its healthiest, will carry Wojo Nutrition's lines ... At Wojo Nutrition, they’ve launched a revolution in the ... tailored to meet their multifaceted goals. Their line of ... any beverage, has been specially formulated to be as ...
(Date:4/21/2015)... Now in its fifteenth year, the TU-Automotive Detroit ... 3,000 senior attendees from across the automotive, technology ... on June 3 and 4. This year leading ... are set to deliver headline and keynote presentations ... as connectivity paves the way towards smart mobility ...
Breaking Medicine News(10 mins):Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 2Health News:TU-Automotive Detroit 2015 Sample Attendee List Released 3
... the $50 million “YES Medical Technology Fund”, a ... companies with revenues and profits to expand their ... will provide growth capital to medtech companies that ... profitable (minimum $2 million EBITDA), and have the ...
... Unilens Vision Inc. (OTC,Bulletin Board: UVICF; TSX Venture Exchange: ... lenses, today reported,its operating results for the first quarter ... Net sales, excluding royalty income, increased ... in the previous year first,quarter (FY2008). The increase ...
... NEW YORK, Nov. 21 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... 17, 2008, it received notice from The Nasdaq Stock ... in compliance with Marketplace Rule 4310(c)(3), which requires the ... equity, or $35,000,000 market value of listed securities, or ...
... DETROIT, Nov. 21 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext US: ... the FDA warning letter on November 24, 2008 as planned.,In ... requested a,response from Caraco within 15 business days, ending November ... previously disclosed, the warning letter was issued as a follow ...
... VTAL ), a leading provider of advanced visualization ... agreed to,renew their global distribution agreement for five years, ... As under the previous agreement, Toshiba will offer ... than 50 nations in North and,South America, Europe, the ...
... surgery but either couldn,t afford it or were afraid of undergoing ... cosmetic surgery with a nonsurgical facelift that,s extremely safe, minimally invasive, ... ask for? , ... Coral Gables, FL (PRWEB) November ...
Cached Medicine News:Health News: Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 4Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter 2Health News:Vital Images and Toshiba Renew Distribution Agreement 2Health News:Vital Images and Toshiba Renew Distribution Agreement 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: